NIAID AIDS Vaccine Selection Committee
Executive Summary
NIAID establishes 12-member committee to help in decisions on which potential AIDS vaccines now being tested in laboratories are "promising enough" to be tested in humans. In addition, committee will recommend minimum guidelines manufacturers must meet for eligibility for Phase I trials and for being considered for Phase II studies. Committee members include PMA VP-Medical and Regulatory Affairs John Petricciani and FDA Biological IND Division Deputy Director Janet Woodcock.
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.